Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

276.50 -0.68 (-0.25%)
Streaming Delayed Price Updated: 1:13 PM EDT, Jul 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
How Do Investors Really Feel About Ascendis Pharma? ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Ascendis (ASND) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Ascendis Pharma? ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Ascendis Pharma? ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Peering Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Is Ascendis Pharma Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of Ascendis Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria ↗
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing? 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock? ↗
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
News headline image
Looking Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock? ↗
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
News headline image
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 12, 2025 ↗
 
Via Benzinga
News headline image
Why Is BioMarin Stock Trading Higher On Thursday? ↗
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
News headline image
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
News headline image
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.